NVAX a buyNASDAQ:NVAX is a buy here. SLO STO reset daily and is higher on the 30-minute chart with a 7/21 EMA cross-over. Targets $18 and above.
NVV1 trade ideas
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in
an ascending channel NVAX is now at the bottom of the channel perhaps due to the general
market moves this week. From here it can move up in the channel or breakdown and fall into
a significant correction from the uptrend since May 10th. I am bullish on NVAX and have
a prior perspective of an insider. I have realized profit six figures from my call options for
January 2025 and have a large number remaining in the trade. At this juncture, I will watch
for NVAX to move up in the channel and take a trade of shares and some call options
for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options.
The FDA is currently reviewing some COVID vaccine data which is particularly relevant to
NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares.
The options will have a 20% stop loss. Considering the level from which NVAX has fallen over
a period of some period there is great potential in my opinion.
NVAX to $45 imoThis thing just ended its cycle of shorts, and made some partnership happen. no resistances for now. $20 will be easy, but with options, you can make some serious gains. January expiry isn't even that expensive
Just be cautious always as it's $2bil market cap, unlike AMZN or MSFT for the trillions.
NFA. Good luck
PS. might wanna peek the dystopian pandemic treaty...
there's a reason you haven't heard about it yet. simple google search will do
Sanofi Set to Take a 4.9% Stake in Novavax for $70 MillionShah Capital has announced the withdrawal of its campaign against the re-election of three directors on Novavax's board following the COVID-19 vaccine maker's licensing deal with Sanofi. The deal, signed on May 10, entails Sanofi taking a 4.9% stake in Novavax for $70 million at a substantial valuation, including an upfront cash payment of $500 million and future payments contingent on specific milestones and royalties. This move comes after Novavax ( NASDAQ:NVAX ) struggled to bring its protein-based vaccine to the market in a timely manner. Furthermore, the company has removed a warning notice from February last year, which cast doubt on its ability to continue operations, signaling increased stability after the deal with Sanofi.
Shah Capital, which holds approximately 7.8% stake in Novavax ( NASDAQ:NVAX ),said that the Sanofi agreement represents a "long-awaited step in the right direction." Despite the withdrawal of its campaign, the fund continues to assert that Novavax ( NASDAQ:NVAX ) would benefit from the addition of a stockholder representative on its board.
Novavax ( NASDAQ:NVAX ) has reaffirmed its commitment to driving long-term value for all shareholders and has welcomed the decision by Shah Capital to end its campaign, deeming it as the right choice for shareholders and the company.
Moreover, Shah Capital remains vigilant, stating its belief that significant additional value remains to be unlocked at Novavax ( NASDAQ:NVAX ).
Technical Outlook
The Maryland-based biotech company's stock rose approximately 8.53% to $14.21 in premarket trading, marking an almost threefold increase in value this year.
Novavax ( NASDAQ:NVAX ) stock has a Relative Strength Index (RSI) of 79.87 which is quite overbought with the asset trying to maintain the new Resistance Level reached by it.
Additionally, as of April 30, the stock's short interest stood at 32% of publicly available shares, according to analytical Data firm LSEG data.
Its a new generation called COVIDGather around the camp fire and lets forgive healthcare and biotech this year... and the last.
This year its different, I want to see the rotation in over valuing vaccine stocks again.
Novavax Surge Over 130% On $1.4 Bln Covid Shot Deal with SanofiNovavax shares ( NASDAQ:NVAX ) surged over 130% after a $1.4 billion deal with Sanofi was announced to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid. The biotech firm announced a licensing agreement with Sanofi to sell Novavax’s Covid vaccine worldwide, with Sanofi paying Novavax $500 million upfront and future payments up to $700 million based on other milestones, in addition to royalties.
Sanofi will receive a sole license to develop and commercialize a combination flu and Covid vaccine containing Novavax’s Covid shot and Sanofi’s flu shot. Novavax ( NASDAQ:NVAX ) is also entitled to launch and sales milestones of up to $200 million for any vaccine developed by Sanofi as part of the deal. The company expects to launch a late-stage trial of its own combination vaccine targeting Covid and the flu and a stand-alone flu shot later this year.
The licensing agreement will likely lift Novavax’s “going concern” warning issued last year, after the company said “substantial doubt exists” to continue operating. A significant uptick for Novavax ( NASDAQ:NVAX ) shares follows yearslong financial woes for the biotech firm. The company cut its 2024 sales forecast in its first-quarter review, decreasing projections from between $800 million and $1 billion to $400 million to $600 million. Novavax ( NASDAQ:NVAX ) also reported a first-quarter net loss of $148 million, compared with a net loss of $294 million during the same period last year.
As part of the deal, Sanofi is also taking a less than 5% equity stake in Novavax, and Novavax ( NASDAQ:NVAX ) will receive royalty payments for future sales of its COVID-19 vaccine and the future combination COVID-19 and flu vaccine. The deal will allow Novavax to lift its “going concern” warning, which was issued in early 2023 over concerns that it may not be able to financially survive as demand for COVID-19 vaccines waned.
Alongside the Sanofi deal, Novavax ( NASDAQ:NVAX ) also reported first-quarter results that missed analyst estimates. Novavax ( NASDAQ:NVAX ) reported revenue for the first quarter of $93.9 million, shy of the $101.3 million analysts expected, and posted a loss of $147.6 million, or $1.05 per share, wider than the loss of $127.4 million, or 90 cents per share, that analysts projected.
For the full fiscal year, Novavax ( NASDAQ:NVAX ) lowered its projected revenue to $400 million to $600 million, down from the previous range of $800 million to $1 billion. However, the estimated $570 million the company expects to receive from Sanofi this year pushed its combined revenue and payments projections higher, to $970 million to $1.17 billion.
Technical Outlook
Novavax ( NASDAQ:NVAX ) is up 98% as of the time of writing, trading above the 200-day Moving Average (MA). The stock has a Relative Strength Index (RSI) of 86.66 which is clearly in an overbought territory. The daily price charts depict an upside or upward gap that occurred as a result of the impending deal.
nvax made the vaccineits not unthinkable this stock exploded and then collapsed. that being said i dont think this particular pop will last long, and thats why im scalping a lower high bullish to countertrend daily averages that should sell off after.
Now what?Seems like 3.5 is a string demand area that pushes the price very hard to the upside. The last time was in Jan 2020. I don't think is going to explode above 30 but the next resistance is at 10. This is a high volatile stock, I bought calls exp 04/19 strike 5.5. If this breaks out will be massive.
Unpopular opinion: new cycle for NOVAVAXNovavax is, besides a big pharma stock and one of the main previous providers of COV!D vaccines, a cyclical stock.
It has been for 20 years, and I'm betting 2% of my portfolio it is going to be again.
Despite the latest earnings, we are in the midst of the early part of the global liquidity cycle, which doesn't mean up-only, but Novavax is likely to be only getting started right now... Who else is going to sell the stock at this price besides perma-bears?!
GM.
Novavax Sees 2024 Sales Flat to Lower, Plummeting By 26.4%In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O).
Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax ( NASDAQ:NVAX ) remains undeterred in its pursuit of market dominance. Chief Executive John Jacobs acknowledges the company's disappointing performance during the recent vaccination campaign, attributing it to delayed market entry and logistical challenges. However, Jacobs remains resolute in his commitment to enhancing Novavax's competitive positioning and expanding its footprint in the burgeoning vaccine landscape.
A key focal point of Novavax's ( NASDAQ:NVAX ) strategy is the pursuit of pre-filled syringes, a format favored by consumers and healthcare providers alike for its convenience and ease of use. Jacobs emphasizes the importance of targeted sales efforts and broad retail availability to drive uptake and accelerate market penetration.
Despite near-term revenue challenges, Novavax ( NASDAQ:NVAX ) remains optimistic about its long-term prospects, projecting revenue for 2024 in the range of $800 million to $1 billion. The company's commitment to cost containment and operational efficiency underscores its determination to navigate uncertainties and drive sustainable growth in the years ahead.
Novavax's ( NASDAQ:NVAX ) journey has been marked by highs and lows, from soaring market valuations to regulatory hurdles and manufacturing setbacks. However, the company's resilience and adaptability position it well to overcome obstacles and emerge as a formidable player in the global fight against COVID-19.
While challenges persist, including lingering doubts about the company's financial viability, Novavax remains focused on execution and delivering value to stakeholders. Jacobs's emphasis on operational improvements and leaner processes reflects a renewed commitment to efficiency and effectiveness in the commercial market.
As Novavax ( NASDAQ:NVAX ) embarks on this pivotal phase of its journey, investors and industry observers await eagerly to witness the company's ability to translate strategy into tangible results. With determination, perseverance, and a renewed sense of purpose, Novavax ( NASDAQ:NVAX ) seeks to redefine its narrative and carve out a prominent place in the annals of vaccine innovation.
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis
NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up.
Novavax Reaches Settlement With Gavi, Paving The Way Forward
In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations.
The Dispute Resolution
Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022.
Impact On Novavax
The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs.
Settlement Terms
Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark.
Strategic Implications For Novavax
The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company.
Looking Ahead
With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities.
Conclusion
In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings
is coming this upcoming week. This week NVAX news release showed it had settled a years long
litigation over a failed COVID. In the face of earnings around the corner, was this news release
a coincidence or instead a case of excellent executive and legal timing? I will skip the
conspiracy discussion.
On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock
that has been stuck in deeply undervalued territory for a significant time period is remarkable.
I have bought far out of the money call options into 2025 and 2026 some only this past month.
Those from this month are now up over 250% with 11 and 23 months to go to expiration.
I see NVAX as a risky penny medical stock with a high reward potential relative to the
risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is
MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out
the competition when there is an opportunity and do not worry about the government crying
monopoly when life-saving and life-extending medical products are involved. Time will tell.
I expect insane profits.
NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period of
consolidation producing the POC line on the volume profile. The MACD shows some bullish
divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative
volume void. NVAX fell quickly through that void. It can just as easily rise through it. See the
linked article on NVA from TipRanks. Options volume and pricing analysis is that bets are looking
at5.0 diligently. Fundamentally, NVAX has been range limited by its focus on COVID but it does
have other projects in its pipeline admittedly on various timelines with varying probabilities
of capitalizing on them depending on clinical trials FDA approvals and so on. On the imbedded
relative strength table as compared with SPY and peers in the pharmaceutical, biotechnology,
medical device and healthcare spaces NVAX compares favorably with MRNA its closest peer
but is weak compared with most of the others I have selected especially with LLY, which is
high-flying from its anti-obesity drug breakout. Device companies Stryker and Intuitive Surgical
are quite strong as well. United Healthcare is dominant in the insurance subsector and strong
overall.
One often effective strategy is to buy when an instrument is oversold and undervalued at a
discount. I will buy NVAX here no matter that I have insider connections with one of those
medical device companies and a few not on the list. Sentiment only goes
so far. I found the article compelling and so Novavax long I go. On a trading site left unsaid
my screenname is "Bottom Feeding Grinder". I have an appetite for NVAX found at the bottom
right now. This is a reversal/reversion to the mean long trade. It is not without risk. As a
penny stock with high volumes, low cost of entry and perhaps low floats, volatility is
underscored and exaggerated if a volume inflow gets underway That said, a short squeeze
is within the spectrum of possibilities. Enough said for now.
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical
triangle. It in now in a breakout of the triangle and in the process when from undervalued on
Monday to the upper trendline and then down to the support trendline and then up again.
It passed through the volume profile and its high volume area. In short, it has bullish
momentum capped off with a breakout from the high volume area into a bullflag to rest the
weekend. I am in this stock going and now is an opportunity to add to the position. If a trader
wants to know what I consider to be targets upside, let me know. Medical technology is
expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I
believe it has significant upside for the long term. in the short term, earnings are expected
on February 28th so this is a trade to consider on that run up. Call options for March 2 or March
16 can be considered.
Nutrix Therapeutics ( NRIX) has momentum for earnings LONGNRIX , on the 15 minute chart is experiencing increase volatility and volume now two
days out from its earnings report. It printed a "big ass" green engulfing candle to finish the
week. The MACD with zero lag shows a bullish inflection in the lines
On the daily chart, price fell about 25% in 2023. earnings have been both line beats but
the negative cash flow remains as a challenge. The volume and volatility show both are
heightened in the pre-earnings run- up. . This is a risky earnings
play, NRIX does not yet make money like many other young biotechnology companies trying to
grow However, because it lost less than forecasted, buyer interest has increased. There is
an absence of any options volume and so illiquidity prevents consideration of options
trading. I suspect a long trade in shares may gain to $14 targeting the pivot highs of
April 23 and November 22 for projected gain upside of about 65% ( stop loss of 2.5%)
If earnings disappoint trader expectations and price fades I will stop out with a loss of about
2.5% This makes this long swing trade a projected 2.5 /65 a R:r of 25 which validates it as
a conservative trade if taking only 5% or less of buyer power applied to the risk. Biotechnology
is expected to be one of the hottest subsectors of 2024. This could be one of them.
$NVAX long base breakoutNASDAQ:NVAX breaking out of base with strong volume after it announced that it reached settlement with Gavi Vaccine Allliance. The longer the base the strongerthe return.
Novavax (NVAX) Wyckoff AccumulationIt looks to me like NVAX is completing a textbook Wyckoff Accumulation schematic. I believe the bottom is in and we've double-tapped the spring. Now it's time for the "wall of worry" as we head back up toward fib extensions. Just my humble opinion.
NVAX I believe that exceeding the 4.35 level is important for a bullish reversal signal, otherwise we could see new lows
NVAX - Big PictureNVAX has been making lower lows since 1998, and price is currently falling towards the descending angle. (orange circles)
Will it touch it again? If price falls below $3 it will.
Looking at the big picture, every time NVAX touched this declining trend line, price went parabolic.
How high could price go?
Look at the purple channel. Price either peaked at the bottom or the top of the parallel channel. (white circles)
It took about six months to three years to go from the bottom of the descending angle to its blow off top. And it saw gains between 10 - 70X.
Where would price retrace to after the blow off top?
Look at the yellow parallel channel. Price retraced to the top of the channel, and eventually fell into this channel, bouncing within this range.
Prices could never find support on the bottom of the channel, and broke below, falling to the descending angle and creating another lower low.
The only exception was in 2012, where price was able to break back out of the channel and reached a blow off top in 2015.
Watch the 21 EMA. (blue moving average) If price bounces off the descending angle, in the future watch when it breaks above the 21 EMA. If price can find support on top of the 21 EMA, it should carry price to its blow off top.
Does a touch of the descending angle guarantee a bounce up to its blow off top in the purple channel?
No. But looking at the history of NVAX, it has done this 4 times since 1998.
Could price touch the descending angle, and fall way lower?
Sure can. $3.54 is NVAXs all time low. Breaking below this price, which it would if it touched the descending angle, would mean there's no support left to prevent price from falling to the pennies. I'm not saying this would happen, but it's possible, especially when price enters unchartered all time lows.
NVAX Looking BearishThis is a split screen of NVAX, both on the weekly time frame.
The chart on the right is the bollinger bands. Currently there's a squeeze and the mouth is just beginning to open. Price is under the white basis line, and if the mouth of the bands begins to open wider, it's likely price will get dragged down and ride the bottom yellow band.
The chart on the left is a line chart with oscillators. Price has been trading within a range since February of 2023. (Yellow parallel channel) It's been bouncing between the $6.35 and $9.50 level. If price breaks below the $6.35 level, it would then test $5.00 as support. (Orange dashed line)
Looking at both the rsi and stochastics, strength and momentum are falling, and are in bearish territory. So there's a chance price could break below the parallel channel.
Couple this with the opening of the bollinger bands, and NVAX looks very bearish.
NOVAVAX we can waitHello investors, we are all looking for the chance to manage our money ourselves and make high profits. I would like to make my own contribution to this. Here is my trade from NOVAVAX. My idea invest 100 eur or usd and get almost 900% profit. Buying and holding is currently the best option. Basically, I advise everyone who follows my recommendations, but also others, to find out about market trends, companies and, above all, future prospects. In the future, I will publish 2 trend positions from the areas of stocks, commodities and cryptocurrencies for review every week. Have fun and good luck
$NVAX Novavax, Inc. Long term PT 360 and higherNASDAQ:NVAX Novavax, Inc.
Long term PT 360 and higher
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Novavax Options Ahead of EarningsIf you haven`t bought NVAX during the Covid Pandemic:
Then analyzing the options chain and the chart patterns of NVAX Novavax prior to the earnings report this week,
I would consider purchasing the 7.50usd strike price Calls with
an expiration date of 2024-1-19,
for a premium of approximately $0.87.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
